





**FIGURE 1**

**FIGURE 2**


# FIGURE 3



**FIGURE 4**

# FIGURE 5


Breast Cancer: MUC1- Positive



A

anti-var-PSMGFR


Breast Cancer: MUC1- Negative



B

C

D




MU4H5

# FIGURE 6

Lung Cancer:

MUC1- Positive

B




A

Anti-var-P<sub>SMGFR\*</sub>


MUC1- Negative

D



C


VU4H5




D

FIGURE 7

A









B



anti-var-PSMGFR

VU4H5

**FIGURE 8****Prostate Cancer****Benign Prostatic  
Hyperplasia****A****anti-var-PSMGFR****B****C****VU4H5****D**

**FIGURE 9****Colon Cancer****anti-ver-PSMGFR****A****B****Normal Colon****C****VU4H5****D**


10/29

# FIGURE 10


VU4H5

anti-var-PSMGFR


H&E




C



B




A


**FIGURE 11**

12/29


# FIGURE 12





## FIGURE 13





# FIGURE 14





**FIGURE 15****Compound No. 173 on T47D, DU 145 and PC3**


**FIGURE 16**


**FIGURE 17****Effect of Compound #173 on MUC1 Transfected HEK 293 Cells**

**FIGURE 18****Effect of Compound No. 28 on MUC1 Transfectants into HEK 293s**

**FIGURE 19****Effect of Compound No. 118 on MUC1 Transfectants**

**FIGURE 20****Effect of Compound No. 125 on MUC1 Transfectants**

**FIGURE 21**

**FIGURE 22****Effect of Compound No. 182 on MUC1 Transfectants**

# FIGURE 23




FIGURE 24






FIGURE 25



# FIGURE 26





**FIGURE 27**

FIGURE 28



**FIGURE 29****Compound No. 173, No. 186 on MUC1  
Transfectants**